Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on February 28, 2003. The report details a strategic acquisition by Genomic Solutions Inc., a wholly-owned subsidiary of Harvard Bioscience, Inc.
Key Financial Metrics
The filing discloses the following financial terms regarding the acquisition:
- Purchase Price: Approximately $8.3 million in cash, subject to certain adjustments.
- Liabilities: The transaction includes the assumption of certain specified liabilities of the target company.
- Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period or the target company.
Material Changes
The primary material event is the execution of an Asset Purchase Agreement to acquire substantially all assets of Genomic Instrumentation Services, Inc. d/b/a GeneMachines. GeneMachines specializes in high-throughput instrumentation for DNA and protein microarray production, nucleic acid sample preparation, and DNA synthesis.
Outlook, Risks, and Contingencies
- Closing Conditions: The transaction is subject to approval by GeneMachines shareholders and other customary conditions.
- Timeline: Closing is expected in mid-March 2003.
- Shareholder Support: The Company has secured a voting agreement with GeneMachines shareholders holding the requisite number of shares to approve the transaction.
- Risk Factors: The filing includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially due to known and unknown risks. Specific risk factors are referenced in the Company's 2001 Form 10-K and Form S-4 filings.
Investor Verification Checklist
- Verify the final closing date of the transaction (expected mid-March 2003).
- Confirm the final purchase price after customary adjustments.
- Review the specific liabilities being assumed as part of the deal.
- Examine the full Asset Purchase Agreement (Exhibit 2.1) for detailed covenants and conditions.
- Assess the integration plan for GeneMachines' high-throughput instrumentation products.